What are the key financial results reported in this 10-Q for Amgen?

The provided text is a directory listing and does not contain the specific financial statements or management's discussion and analysis. To determine the key financial results, one would need to access and review the actual content of the filed 10-Q report, which would detail revenues, net income, earnings per share, and cash flows for the quarter ending March 30, 1995.

What were Amgen's main products and their performance during this period?

This filing excerpt does not specify Amgen's product lines or their performance. A comprehensive review of the full 10-Q report would be necessary to identify key products like Epogen and Neupogen and understand their sales figures, growth rates, and any related market commentary from management.

Are there any significant developments or risks mentioned by Amgen's management in this filing?

The provided text is a navigational index and does not include the Management's Discussion and Analysis (MD&A) section. Investors would need to consult the full 10-Q document to find management's commentary on the company's performance, strategic initiatives, known risks, and future outlook.

How can I access the full 10-Q filing to get detailed financial information?

The provided text indicates the filing was made through the SEC's EDGAR system. Investors can typically access full SEC filings by searching the EDGAR database on the SEC's official website (sec.gov) using the company name (Amgen Inc.) or ticker symbol (AMGN) and the filing date.

AMGN 10-Q Quarterly Report Q1 FY1995 — Revenue, Net Income, EPS

Summary

Amgen Inc.'s Form 10-Q for the period ending March 30, 1995, provides a snapshot of its financial performance and operational status during the first quarter of the year. While the provided text is primarily navigational and metadata related to the filing, it indicates that Amgen was actively reporting its financial activities, a crucial aspect for investors seeking to understand the company's trajectory. Investors in Amgen at this time would be keenly interested in revenue growth, product sales performance (particularly for key drugs like Epogen and Neupogen), and any significant research and development advancements or setbacks. The filing context suggests a company in a growth phase, likely navigating the complexities of the biotechnology market, including regulatory approvals, market penetration, and competition. Therefore, any information within the actual financial statements and management discussion would be vital for assessing the company's valuation, future prospects, and the associated risks. Investors would look for details on profitability, cash flow generation, and strategic investments that could shape Amgen's long-term value.

Key Highlights

1The filing pertains to Amgen Inc. for the quarter ending March 30, 1995, providing a specific historical financial update.
2This report is a Form 10-Q, indicating a standard quarterly disclosure required by the SEC for publicly traded companies.
3The filing date of May 14, 1995, suggests that the financial data reported reflects performance up to the end of the first quarter of that year.
4Investors can infer that Amgen was an active, publicly traded entity requiring regular financial reporting to the market.
5The nature of a 10-Q filing implies a review of financial statements, including balance sheets, income statements, and cash flow statements, along with management's discussion and analysis.
6The filing likely contains information on revenue, expenses, profitability, and potentially details on Amgen's product pipeline and commercial performance of its biopharmaceutical products.

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 1995

Summary

Key Highlights

Frequently Asked Questions